Reading PIII? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PIII free→Reading PIII? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PIII free→
NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed, and it has a capital-unfriendly stance. Risk is high, and the sector backdrop is a headwind, which may impact future performance. If PIII reverses and cuts guidance after recently raising, that could lead to a credibility hit, which is a significant concern. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $11.69. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 1.31x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, the broad stock market, Fed net liquidity.
14 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $-1.90. 0 raised, 1 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 50% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$461.
How much price usually moves either way.
On a bad day, this stock has moved -$1,128.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,508.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PIII yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 28, 2025, P3 Health Partners Inc. (the “Company”) received a letter from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it did not comply with at least one of the following standa…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Facilities.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PIII P3 Health Partners Inc | Above typical Show detailsSector percentile: 72 of 100 | — | high |
HCA HCA Healthcare | Above typical Show detailsSector percentile: 81 of 100 | fair | moderate |
THC Tenet Health | Above typical Show detailsSector percentile: 87 of 100 | fair | elevated |
EHC Encompass Health | Above typical Show detailsSector percentile: 97 of 100 | full | moderate |
UHS Universal Health Services | Above typical Show detailsSector percentile: 93 of 100 | inexpensive | elevated |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to increase total revenue to between $1.5 billion and $1.7 billion for the fiscal year 2026.
Stated in 2 of last 2 quarters. Revenue grew from $345.3M in 2025-Q3 to $386.4M in 2026-Q1, indicating progress towards the $1.5B-$1.7B target for 2026. The trajectory shows delivering growth.
“Total Revenues (in millions) $1,500 $1,700”
“Total Revenues (in millions) $1,500 $1,700”
Management has raised the full-year 2026 adjusted EBITDA outlook to a midpoint of $40 million.
Newly stated in 2026-Q1. Management has set a target to raise adjusted EBITDA to $40M for 2026. While the financials show a positive net income of $1.2M in 2026-Q1, the trajectory towards the EBITDA target remains to be seen.
“raising our full-year 2026 adjusted EBITDA outlook to a midpoint of $40 million”
Management is focused on addressing compliance issues related to Nasdaq listing standards.
Newly stated in 2026-Q1. The company received a notice regarding Nasdaq listing compliance issues. While management's focus on addressing this is clear, the financials do not yet reflect any resolution or impact on compliance.
“Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard”
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
Results of Operations and Financial Condition. On May 14, 2026, P3 Health Partners Inc. (the “Company”) announced its financial results for the three months ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”). The information in this Item 2.02, including the information contained in Exhibit 99.1 of this Report, shall not be deemed “filed” for purposes of Section 18 of…
Entry into a Material Definitive Agreement
Unregistered Sales of Equity Securities